SecBot SecBot
8-K ·Filed May 8, 2026

VASO

VASO Corp
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001213900-26-053854
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine compensatory arrangement with no material financial impact. Monitor future filings for disclosure of whether the strategic objectives were achieved, which could signal a corporate event, but the $175,000 amount is immaterial relative to any potential transaction.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
VASO ▲ +26.00% at T+60d
NEUTRAL call +26.00% · α vs SPY +21.61% · entry $0.2000 → $0.2520
Entry = T+0 close
May 8, 2026
via day close
T+1d
0.00%
call 0.00% · α +0.14%
$0.2000
settled 6mo ago
T+5d
+25.00%
call +25.00% · α +25.09%
$0.2500
settled 6mo ago
T+20d
-5.00%
call -5.00% · α -4.70%
$0.1900
settled 5mo ago
T+60d
+26.00%
call +26.00% · α +21.61%
$0.2520
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

VASO Corp entered into an incentive agreement with Peter Castle, President of its wholly-owned subsidiary VasoTechnology Inc., on May 4, 2026. Mr. Castle can earn a $175,000 payment if specified strategic initiative objectives are achieved within the agreement's time period. This is a routine compensatory arrangement for a subsidiary president with no departure or appointment of directors or officers.

Key Facts

  • Agreement dated May 4, 2026 with Peter Castle, President of VasoTechnology Inc. (wholly-owned subsidiary)
  • Incentive payment of $175,000 tied to achieving specified corporate outcomes related to potential strategic initiatives
  • No payment if objectives are not achieved within the specified time period
  • No departure, resignation, or appointment of directors or officers reported
  • CEO Jun Ma remains in place

Financial Impact

Maximum incentive payment of $175,000 if strategic objectives are met

compensation expense

Risk Factors

  • No risk of material adverse impact from this filing

Market Snapshot

Exchange
OTC
Sector
Electromedical & Electrotherapeutic Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-053854
Document: 0001213900-26-053854-index-headers.html0001213900-26-053854
Document: 0001213900-26-053854-index.html0001213900-26-053854
Document: 0001213900-26-053854.txt0001213900-26-053854

US Market Status

Market Closed — Opens Thu (10h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 8, 2026